Dyslipidemia in chronic kidney disease: Managing a high-risk combination

Postgraduate Medicine

Volumn 121, Issue 6, 2009, Pages 54-61

  Chauhan, Veeraish ^a   Vaid, Megha ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Dyslipidemia; End stage renal disease; Statins

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLOFIBRATE; CORTICOSTEROID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; GRAPEFRUIT EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; PYRROLE DERIVATIVE; RAPAMYCIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; WARFARIN; ANTILIPEMIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; MORTALITY; MYOPATHY; MYOSITIS; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PHYSICIAN; PLEIOTROPY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY CARE PHYSICIAN; PROGNOSIS; RENAL PROTECTION; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; CHRONIC KIDNEY FAILURE; DISEASE COURSE; REVIEW;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC;

EID: 73949144143     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.11.2077     Document Type: Article

References (38)

1. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis. 2003;41(suppl 3):S1-S92.
2. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32(5):853-906.
3. Fox CH, Voleti V, Khan LS, Murray B, Vassalotti J. A quick guide to evidence based chronic kidney disease care for the primary care physician. Postgrad Med. 2008;120(2):E01-E06.
4. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
5. Sekkarie M, Cosma M, Mendelssohn D. Nonreferral and nonacceptance to dialysis by primary care physicians and nephrologists in Canada and the United States. Am J Kidney Dis. 2001;38(1):36-41.
6. Keane WF, Kasiske BL. O'Donnell MP. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol. 1988;8(4):261-271.
7. Mühlfeld AS, Spencer MW, Hudkins KL, Kirk E, LeBoeuf RC, Alpers CE. Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice. Kidney Int. 2004;66(4):1393-1402.
8. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12(9):1908-1915.
9. Rahman M, Baimbridge C, Davis BR, et al; ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Am J Kidney Dis. 2008;52(3):412-424.
10. Shepherd J, Kastelein JJ, Bittner V, et al; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131-1139.
11. Fellström B, Holdaas H, Jardine AG, et al; AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res. 2007;30(5):314-322.
12. Wanner C, Krane V, März W, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-248.
13. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;(84):S207-S10.
14. Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19(10):1045-1052.
15. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Disease. 1998;32(5 suppl 3):S142-S156.
16. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P. Dialysis modalities and dyslipidemia. Kidney Int Suppl. 2003;(84):S110-S112.
17. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Neprol Dial Transplant. 1998;13(11):2833-2841.
18. Liu Y, Coresh J, Eustace J, et al. Association between cholesterol level and mortality in dialysis patients: rote of inflammation and malnutrition. JAMA. 2004;291(4):451-459.
19. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol. 2007;18(1):304-311.
20. Volpato S, Zuliani G, Guralnik JM, Palmieri E, Fellin R. The inverse association between age and cholesterol levels among older patients: the role of poor health status. Gerontology. 2001;47(1):36-45.
21. Grundy SM, Cleeman JI, Merz CN; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-732.
22. Holdaas H, Fellström B, Jardine AG, et al; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024-2031.
23. Baigent C, Landray M, Leaper C, et al; First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473-484.
24. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33(9):2337-2341.
25. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B-12B.
26. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M):M8-M14.
27. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413-1419.
28. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993;104(1-2):159-171.
29. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol. 1993;3(7):1409-1415.
30. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia. with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993;87(4 suppl):III45-III53.
31. Harris KP, Wheeler DC, Chong CC; Atorvastatin in CAPD Study Investigators. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int. 2002;61(4):1469-1474.
32. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39(6):1213-1217.
33. Tonelli M, Moyé L, Sacks FM; Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138(2):98-104.
34. Atthobari J, Brantsma AH, Gansevoort RT, et al; PREVEND study group. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant. 2006;21(11):3106-3114.
35. Gotto AM Jr, Farmer JA. Pleitropic effects of statins: do they matter? Curr Opin Lipidol. 2001;12(4):391-394.
36. Munford RS. Statins and the acute-phase response. N Engl J Med. 2001;344(26):2016-2018.
37. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899-1911.
38. Kasiske B, Cosio FG, Beto J, et al; National Kidney Foundation. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4(suppl 7):13-53.